Style | Citing Format |
---|---|
MLA | N Dinarvand NEGAR, et al.. "Evaluation of Myc Oncogene Expression in Human Breast Cancer and Its Relationship With Acsl4 and Lipin-1 Expression." Advanced Biomedical Research, vol. 13, no. 1, 2024, pp. -. |
APA | N Dinarvand NEGAR, R Azizi REZA, S Rastaghi SEDIGHEH, F Karimi FARZANEH, A Sheikhi ABDOLKARIM, M Pourfarzam MORTEZA (2024). Evaluation of Myc Oncogene Expression in Human Breast Cancer and Its Relationship With Acsl4 and Lipin-1 Expression. Advanced Biomedical Research, 13(1), -. |
Chicago | N Dinarvand NEGAR, R Azizi REZA, S Rastaghi SEDIGHEH, F Karimi FARZANEH, A Sheikhi ABDOLKARIM, M Pourfarzam MORTEZA. "Evaluation of Myc Oncogene Expression in Human Breast Cancer and Its Relationship With Acsl4 and Lipin-1 Expression." Advanced Biomedical Research 13, no. 1 (2024): -. |
Harvard | N Dinarvand NEGAR et al. (2024) 'Evaluation of Myc Oncogene Expression in Human Breast Cancer and Its Relationship With Acsl4 and Lipin-1 Expression', Advanced Biomedical Research, 13(1), pp. -. |
Vancouver | N Dinarvand NEGAR, R Azizi REZA, S Rastaghi SEDIGHEH, F Karimi FARZANEH, A Sheikhi ABDOLKARIM, M Pourfarzam MORTEZA. Evaluation of Myc Oncogene Expression in Human Breast Cancer and Its Relationship With Acsl4 and Lipin-1 Expression. Advanced Biomedical Research. 2024;13(1):-. |
BibTex | @article{ author = {N Dinarvand NEGAR and R Azizi REZA and S Rastaghi SEDIGHEH and F Karimi FARZANEH and A Sheikhi ABDOLKARIM and M Pourfarzam MORTEZA}, title = {Evaluation of Myc Oncogene Expression in Human Breast Cancer and Its Relationship With Acsl4 and Lipin-1 Expression}, journal = {Advanced Biomedical Research}, volume = {13}, number = {1}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - N Dinarvand NEGAR AU - R Azizi REZA AU - S Rastaghi SEDIGHEH AU - F Karimi FARZANEH AU - A Sheikhi ABDOLKARIM AU - M Pourfarzam MORTEZA TI - Evaluation of Myc Oncogene Expression in Human Breast Cancer and Its Relationship With Acsl4 and Lipin-1 Expression JO - Advanced Biomedical Research VL - 13 IS - 1 SP - EP - PY - 2024 ER - |